Marrakchi, Slaheddine
Puig, Lluis
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Accepted: 26 October 2021
First Online: 21 January 2022
Declarations
:
: This article has been published as part of a journal supplement wholly funded by Boehringer Ingelheim.
: Medical writing support was funded by Boehringer Ingelheim.
: Lluis Puig has received honoraria or fees for serving on advisory boards, as a speaker, and as a consultant, as well as grants as an investigator from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, JS BIOCAD, LEO Pharma, Lilly, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB. Slaheddine Marrakchi has received consulting fees from Boehringer Ingelheim.
: Not applicable.
: Not applicable.
: The sponsor of the supplement and all authors identified and discussed the concept for each chapter and the supplement as a whole; further development of each review article was at the direction of the authors who provided guidance to OPEN Health on the content of the article, critically revised the work, and approved the content for publication.
: Not applicable.
: Not applicable.
: Not applicable.